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Abstract The ability of Syk protein tyrosine kinase (PTK) to
phosphorylate peptides, where tyrosine had been replaced by
conformationally constrained analogs, has been exploited to
develop highly selective substrates suitable for the speci¢c mon-
itoring of Syk activity. In particular we have synthesized a
peptidomimetic, RRRAAEDDE(L-Htc)EEV (syktide), with the
3(S)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid
residue (L-Htc) replaced for tyrosine, which is phosphorylated
by Syk with remarkable e⁄ciency (Kcat = 73 min31, Km = 11
WM), while it is not a¡ected to any appreciable extent by a
number of PTKs tested so far. These properties make syktide
the ¢rst choice substrate for the speci¢c monitoring of
Syk. 5 2002 Federation of European Biochemical Societies.
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1. Introduction
Protein phosphorylation is the most general and frequent
mechanism controlling nearly all aspects of cell life. About
one third of mammalian proteins contain covalently bound
phosphate and the phosphorylating enzymes, protein kinases,
encoded by the human genome, are more than 500 [1]. It is
not surprising therefore that protein kinases play a key role in
nearly all signal transduction pathways and that altered func-
tions of individual protein kinases underlie numerous patho-
logical conditions with special reference to neoplastic growth
[2]. Nowadays, a large proportion of potential targets for
pharmacological treatment are indeed protein kinases. Given
these premises, the development of reagents suitable for the
speci¢c monitoring and inhibition of individual protein ki-
nases is a crucial goal in the ¢eld of signal transduction and
related pathologies.
Ser/Thr speci¢c protein kinases often display a stringent site
speci¢city dictated by a number of local determinants [3]
which can be exploited to generate highly discriminatory pep-
tide substrates, readily phosphorylated by just one or a few
related enzymes, while being almost una¡ected by most of the
others [4]. In contrast, the speci¢city of tyrosine kinases is not
strictly dependent on the sequence of the phosphoacceptor site
[3]. This feature, which may well re£ect the tendency of pro-
tein tyrosine kinases (PTKs) to recognize their targets through
adhesion modules located outside the catalytic site, has ham-
pered the design of highly selective peptide substrates based
on sequence distinctiveness, like those successfully used for the
speci¢c monitoring of many Ser/Thr protein kinases. Such a
situation is exempli¢ed by the widespread use of two ‘univer-
sal’ substrates, random polymers of glutamic acid and tyro-
sine (notably polyE4Y) and angiotensin II (DRVYIHPF), re-
spectively, to assay nearly every kind of PTK [4]. Especially
telling is, in this connection, the observation that these two
quite unrelated substrates are readily phosphorylated by
PTKs belonging either to the Src family, whose optimal rec-
ognition sequence includes a hydrophobic residue at position
n31 [5] (present in angiotensin but not in polyE4Y) or to the
Syk family, which instead displays a marked preference for
acidic residues [6,7], an obvious feature of polyE4Y but not of
angiotensin.
An alternative strategy for rendering the selectivity of pep-
tide substrates of PTKs more stringent than that a¡orded by
sequence speci¢city could take advantage of the observation
that the replacement of tyrosine by arti¢cial phosphorylatable
analogs with conformational constraints is variably tolerated
by the di¡erent classes of tyrosine kinases [8^12]. Here we
show the usefulness of this approach for the development of
peptide substrates which can be readily phosphorylated by
Syk, while being practically una¡ected by Src family enzymes
as well as by other tyrosine protein kinases including those
present in crude spleen extracts.
2. Materials and methods
2.1. Materials
[Q32P]ATP was purchased from Amersham Pharmacia Biotech. Pro-
tease inhibitor cocktail and PP2 inhibitor were obtained from Boehr-
inger and Calbiochem, respectively. Modi¢ed angiotensin II
(DRVYIHPFR) was kindly provided by Dr. Oriano Marin (Univer-
sity of Padua, Italy). Anti-Syk, anti-Lyn, anti-c-Fgr and anti-Csk were
from Santa Cruz Biotechnology.
2.2. Peptides
Peptides were synthesized by solid phase using Fmoc chemistry in
0.25 mM scale on an ABI 431A peptide synthesizer according to the
protocol provided by ABI [13] using a Wang resin [14]. Fmoc-[Hba-
Gly]-OH was synthesized starting from phthaloyl-Tyr(Bzl)-Gly-OH
[15] adapting the method described by Flynn and de Laszlo for the
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corresponding Phe analog. 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetrameth-
yl uronium hexa£uorophosphate (HBTU)/1-hydroxybenzotriazole ac-
tivation employed a three-fold molar excess (1 mM) of Fmoc-amino
acids in N-methyl pyrrolidone^dimethylformamide (1:1) solution for
each coupling cycle. Deprotection was performed with 20% piperidine.
In the coupling to the secondary amino groups of L- or D-Htc, the
activation of the K-carboxylic moiety of glutamic acid derivative was
performed using O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uro-
nium hexa£uorophosphate instead of HBTU [16]. Cleavage from
the resin and deprotection were performed by treatment with tri-
£uoroacetic acid^anisole^triisopropylsilane^H2O (82:8.5:8.0:1.5 v/v).
Peptides were puri¢ed by preparative reversed-phase HPLC and char-
acterized by analytical HPLC, amino acid analysis of the acidic hy-
drolysates, and matrix assisted laser desorption ionization^mass spec-
trometry.
2.3. PTKs
Lyn, c-Fgr, Syk and Csk were puri¢ed from rat spleen to near
homogeneity as previously described [17^20]. Recombinant ZAP70
was purchased from Upstate (Lake Placid, NY, USA). They were
routinely assayed on polyGlu4Tyr [17]. One unit was de¢ned as the
amount of enzyme transferring 1 pmol phosphate per minute to
0.1 mg/ml polyGlu4Tyr under standard conditions.
2.4. Resolution of PTKs by heparin-Sepharose chromatography
Crude extract from rat spleen particulate fraction was subjected to
heparin-Sepharose column chromatography [17]. Tyrosine kinase ac-
tivity was monitored by assaying 10 Wl of the fractions on either
polyGlu4Tyr [17] or syktide (see Section 2.5). 30 Wl of fractions was
subjected to SDS^PAGE. Proteins were transferred to nitrocellulose
membranes, incubated with the indicated antibody followed by the
appropriate biotinylated second antibody and developed using an en-
hanced chemiluminescent detection system.
2.5. Peptide phosphorylation
Peptides were phosphorylated in 40 Wl of a medium containing
50 mM Tris^HCl, pH 7.5, 5 mM MnCl2 (5 mM MgCl2 in the case
of c-Fgr), 30 WM [Q32P]ATP (speci¢c activity 1000 cpm/pmol) and 10 U
enzyme. The reactions were terminated after 10 min by addition of
1 ml HCl and processed as described elsewhere [6]. The phosphoryla-
tion of EDDE(L-Htc)EEV was also assessed by reversed-phase HPLC.
The puri¢ed phosphoderivative was analyzed by ESI^MS, giving the
expected MW of 1157.32 (M+Kþ). In the case of angiotensin-R and
syktide, which contain three positively charged residues, the phospho-
cellulose paper procedure to quantify 32P incorporation into peptides
was applied [21]. Km and Kcat values were calculated from double-
reciprocal plots constructed from initial rate measurements ¢tted lin-
early to the Lineweaver^Burk representation of the Michaelis^Menten
equation.
2.6. Tyrosine kinase autophosphorylation
Autophosphorylation was performed as in Section 2.5, omitting the
peptide substrate. Samples were then subjected to SDS^PAGE and
32P incorporated was evaluated by a Packard imager.
3. Results
The structures of the constrained tyrosine analogs, 3(S)- or
3(R)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxyl acid
(either the L or D isomer) and 8-hydroxy-4(S)-amino-1,3,4,
5-tetrahydro-3-oxo-2H-benzazepine-2-acetic acid, henceforth
termed Htc and Hba-Gly, respectively, are shown in Fig. 1.
These analogs were replaced for tyrosine in peptides already
known to undergo phosphorylation by non-receptor PTKs
Syk, Lyn, c-Fgr and Csk.
The e¡ects of these substitutions in the very acidic peptide
EDDEYEEV, an excellent substrate of Syk [6], are shown in
Table 1. The phosphorylation of the L-Htc peptide, tested at
25 WM concentration, is almost identical to that of the parent
peptide, while the D-Htc peptide is almost una¡ected by Syk.
The formation of a stable phosphoderivative of the L-Htc res-
idue was con¢rmed by ESI^MS analysis of the phosphopep-
tide as speci¢ed in Section 2. The Hba-Gly substitution is
quite well tolerated, albeit slightly less than the L-Htc one.
In contrast, the L-Htc substitution suppresses the ability of
the peptide EDNEYTA to undergo phosphorylation by the
Src family kinases Lyn and c-Fgr (Table 1) and by Csk (not
shown).
To check whether the failure of Src family kinases to phos-
phorylate L-Htc peptides was due to their inability to bind the
peptides or to catalyze the phosphate transfer to the Htc
hydroxyl group, competition experiments were performed,
where the Htc derivative of a tyrosyl peptide phosphorylat-
able by the di¡erent tyrosine kinases was tested as a potential
inhibitor of the kinase reaction. As shown in Fig. 2A the
phosphorylation of DRVYIHPF-R (angiotensin II containing
an additional Arg residue at the C-terminus), a promiscuous
peptide substrate for many tyrosine kinases, is inhibited by the
L-Htc peptide in a dose dependent manner if Syk is the cata-
lyst, while it is una¡ected whenever the phosphorylating
agents are Lyn, c-Fgr or Csk. The same is observed if the
tyrosine kinase activities are monitored in terms of autophos-
Fig. 1. Structure of tyrosine analogs.
Table 1
Phosphorylation rates of peptides containing either Tyr or its ana-
logs by di¡erent tyrosine kinases
Protein
kinase
Peptide substrate Peptide phosphorylation
(pmol 32P incorporated/min)
Syk EDDEYEEV 40
Syk EDDE(L-Htc)EEV 44
Syk EDDE(D-Htc)EEV 4
Syk EDDE(Hba-Gly)EEV 33
Lyn EDNEYTA 37
Lyn EDNE(L-Htc))TA 6 1
c-Fgr EDNEYTA 32
c-Fgr EDNE(L-Htc))TA 6 1
Peptide and enzyme concentrations were 25 WM and 10 U, respec-
tively. Data are the means of ¢ve separate experiments. S.E.M. val-
ues were always less than 18%.
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phorylation (Fig. 2B). It can be concluded therefore that the
replacement of Tyr by L-Htc abrogates the ability of the pep-
tide to bind to the active site of the Src family kinases. Con-
sequently, L-Htc peptides could also be exploited to probe the
implication of Syk instead of Src family kinases in the phos-
phorylation of a given protein substrate whose phosphoryla-
tion will be inhibited only if Syk is the phosphorylating agent.
On the other hand, the D-Htc derivative, which is not phos-
phorylated by Syk, is also unable to interfere with Syk medi-
ated phosphorylation of angiotensin-R (not shown), indicat-
ing that the D conformation, unlike the L one, cannot be
accommodated into the active site of Syk.
The kinetic constants reported in Table 2 show that the
e⁄cient phosphorylation of EDDE(L-Htc)EEV by Syk is ac-
counted for by both Kcat, which is even higher than that of the
tyrosyl peptide, and Km, whose value, albeit somewhat higher
than that of tyrosyl peptide, remains nevertheless in the low
WM range. Table 2 also shows that Tyr substitution by L-Htc
is generally tolerated by Syk irrespective of the amino acid
sequence surrounding the phosphorylatable residue, although
some variability can be observed, mostly accounted for by
di¡erences in the increase of Km values.
The data of Table 2 show that EDDE(L-Htc)EEV is by far
the best phosphoacceptor substrate among the L-Htc peptides
tested. We decided therefore to improve its assay by making
applicable the fast and handy phosphocellulose paper proce-
dure, which requires the presence of at least two positively
charged side chains in the phosphorylated peptide. To this
purpose an RRRAA tag was added to the N-terminal side
of EDDE(L-Htc)EEV, giving the peptide RRRAAEDDE-
(L-Htc)EEV, henceforth termed syktide, which is phosphory-
lated by Syk with an e⁄ciency similar to that of the parent
L-Htc peptide (see Table 2). As shown in Fig. 3, the phos-
phorylation of syktide by tyrosine kinases other than Syk,
notably Lyn, c-Fgr, and Csk, is hardly detectable. Quite in-
terestingly, syktide also discriminates between Syk and the
related kinase ZAP70, which phosphorylates the syktide to a
negligible extent as compared to Syk.
Fig. 2. E¡ect of L-Htc analog on either angiotensin phosphorylation
(A) or autophosphorylation (B) activities of di¡erent tyrosine ki-
nases. EDDE(L-Htc)EEV and EDNE(L-Htc)TA were used as inhibi-
tors of either Syk or Lyn, c-Fgr and Csk, respectively. Enzyme ac-
tivity on angiotensin-R was quanti¢ed by phosphocellulose papers,
which cannot bind L-Htc derivatives. Data are the means of four
separate experiments. S.E.M. values were always less than 16%.
Table 2
Kinetic constants for Syk tyrosine kinase of peptides containing either Tyr or L-Htc
Peptide Kcat (min31) Km (WM) E⁄ciency (Kcat/Km)
1 EDNEYTA 72.5 58 1.25
2 EDNE(L-Htc)TA 61.3 185 0.33
3 EDNEYTAEDNEYTA 60.3 27 2.23
4 EDNE(L-Htc)TAEDNE(L-Htc)TA 65.2 60 1.08
5 c(EDNEYTAEDNEYTA) 46.0 6 7.66
6 c(EDNE(L-Htc)TAEDNE(L-Htc)TA) 54.9 31 1.77
7 EDDEYEEV 62.2 3 20.73
8 EDDE(L-Htc)EEV 70.3 7 10.04
9 R3A2EDDE(L-Htc)EEV 73.1 11 6.64
Synthesis and structure of cyclic peptides 5 and 6 are described elsewhere [27].
Fig. 3. Time courses of R3A2EDDE(L-Htc)EEV (syktide) phosphor-
ylation by di¡erent tyrosine kinases. Syk (b), Csk (a), ZAP70 (U),
c-Fgr (F) and Lyn (E). Peptide and enzyme concentrations were
25 WM and 10 U, respectively. Data are the means of four separate
experiments except in the case of ZAP70, whose time course is the
mean of two experiments.
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To further assess the selectivity of the L-Htc peptide for just
Syk among a variety of other kinases, the tyrosine kinase
activities present in a crude spleen preparation were resolved
by heparin-Sepharose column chromatography and monitored
using either the non-speci¢c substrate polyE4Y or the newly
developed syktide. As shown in Fig. 4, the polyE4Y pro¢le is
highly heterogeneous, giving rise to several peaks accounted
for by a variety of PTKs, which are especially abundant in
spleen. In contrast, only one sharp peak eluted by 0.37 M
NaCl was detected using the novel peptide substrate and its
identi¢cation with Syk was corroborated by Western blot
analysis with anti-Syk antibody. No reaction with anti-Syk
antibody could be detected in the fractions eluted elsewhere,
in which Lyn, c-Fgr, Fyn and Csk, still partially overlapping
each other, were detectable by the speci¢c antibodies. Addi-
tional validation of the syktide as a valuable tool for discrim-
inating between Syk and kinases of the Src family was pro-
vided by showing that, while more than 60% of a spleen
extract overall PTK activity assayed on angiotensin-R is ab-
rogated by PP2, a speci¢c inhibitor of Src kinases, the activity
revealed by syktide was fully una¡ected by PP2 treatment (not
shown).
4. Discussion
The data presented show that, at variance with all the other
PTKs tested, Syk tolerates quite well the replacement of ty-
rosyl residues by the conformationally constrained analogs
Htc and Hba-Gly, whose phosphorylation e⁄ciency remains
similar to that of tyrosine. This behavior likely re£ects unique
features of the phosphoacceptor substrate binding site of Syk
as compared to that of the other PTKs, since the constrained
derivatives also fail to compete against the phosphorylation of
tyrosyl peptides by tyrosine kinases unable to phosphorylate
them, notably those belonging to the Src family. While the
structural bases of such an unusual substrate speci¢city of Syk
remain a matter of conjecture, advantage has been taken of
this property to generate an optimal peptide substrate in terms
of both phosphorylation e⁄ciency and selectivity. This goal
has been achieved by including the L-Htc phosphorylatable
residue into an acidic context especially suited for Syk and
by adding to its N-terminus a basic tag which makes applica-
ble the quick and handy phosphocellulose paper procedure for
the evaluation of incorporated radiolabeled phosphate. The
resulting peptide, RRRAAEDDE(L-Htc)EEV, for which we
have proposed the name ‘syktide’, is the ¢rst choice substrate
available to date for the speci¢c monitoring of Syk as judged
both from its failure to undergo phosphorylation by a number
of other PTKs and its ability to detect Syk alone amid a
plethora of PTKs present in crude spleen extracts. Further
investigation is required in order to assess how absolute the
speci¢city of syktide for Syk is. It should be highlighted how-
ever that, somewhat surprisingly, syktide is only very poorly
phosphorylated by the Syk-related kinase ZAP70. This ¢nding
suggests that, despite their relatedness, Syk and ZAP70 di¡er-
entiate signi¢cantly in site speci¢city. This also provides a
biochemical tool for readily distinguishing between Syk and
ZAP70 activities in crude extracts. The ability of the syktide
to reveal the activity of Syk among those of the other non-
receptor PTKs, in particular those of the Src family, makes it
a valuable tool for studies aimed at the identi¢cation of ki-
nases implicated in signal transduction. It should be borne in
mind in this connection that Syk, besides playing an essential
role in hematopoietic cells and in particular in immunorecep-
tor signalling [22,23], has recently been shown to display anti-
neoplastic [24,25] and anti-neurodegenerative potentials [26].
Therefore the availability of reagents, like the syktide, able to
discriminate Syk activity from those of other kinases will
prove helpful for the unraveling of the molecular mechanisms
underlying such biological e¡ects.
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